2′-岩藻糖基乳糖作为人乳寡糖中含量最多的一种,对婴幼儿健康生长发育有重要作用,是极具应用价值的母乳概念配方奶粉添加剂。该研究通过比较不同来源的α-1,2-岩藻糖基转移酶,选定幽门螺杆菌来源的α-1,2-岩藻糖基转移酶基因fucT2与脆弱拟杆菌来源的L-岩藻糖激酶基因fkp共表达,构建了2′-FL的补救合成途径。对乳糖转运蛋白LacY以及2′-FL运出蛋白伯氏耶尔森氏菌来源的糖转运蛋白Tpyb或大肠杆菌来源的糖转运蛋白SetA适量过表达,大幅增加了胞外产物浓度。比较BL21(DE3)、C41(DE3)、JM109(DE3)这3种菌株的2′-FL合成能力,得到了基于JM109(DE3)的2′-FL最终合成菌株J2-V8。通过发酵条件优化,在摇瓶中48 h得到2′-FL的胞外质量浓度为2.67 g/L,较初始菌株提高了5倍,转化率为0.82 mol/mol岩藻糖,以上结果为2′-FL的生物制备技术开发提供了借鉴。
2′-Fucosyllactose (2′-FL) is one of the most abundant oligosaccharides found in human milk, which delivering many health benefits to the neonate. It is now available in some commercial infant formulas with great market potentials. In this study, salvage pathway was constructed by comparing α-1,2-fucosyltransferases from different sources, and choosing the co-expression of fucT2 from Helicobacter pylori and fkp. Then by over-expressing the substrate transporter LacY and product transporter Tpyb or SetA, the extracellular concentration of 2′-FL was greatly increased. Comparing the production capacity of BL21(DE3), C41(DE3), and JM109(DE3), the 2′-FL synthetic strain J2-V8 was obtained. Finally, through the optimization of fermentation conditions, the extracellular concentration of 2′-FL was 2.67 g/L in shaker for 48 h, which was 5 times higher than that of the initial strain, and the conversion rate was 0.82 mol/mol L-fucose, which provided a reference for the biological production technology of 2′-FL.
[1] HORTA B L.Breastfeeding:Investing in the future[J].Breastfeeding Medicine, 2019, 14(S1):S11-S12.
[2] CHUTIPONGTANATE S, MORROW A L, NEWBURG D S.Human milk oligosaccharides:Potential applications in COVID-19[J].Biomedicines, 2022, 10(2):346.
[3] HEGAR B, WIBOWO Y, BASROWI R W, et al. The role of two human milk oligosaccharides, 2′-fucosyllactose and lacto-N-neotetraose, in infant nutrition[J].Pediatric Gastroenterology Hepatology & Nutrition, 2019, 22(4):330-340.
[4] ZEHRA S, KHAMBATI I, VIERHOUT M, et al.Human milk oligosaccharides attenuate antigen-antibody complex induced chemokine release from human intestinal epithelial cell lines[J].Journal of Food Science, 2018, 83(2):499-508.
[5] HICKEY R M.The role of oligosaccharides from human milk and other sources in prevention of pathogen adhesion[J].International Dairy Journal, 2012, 22(2):141-146.
[6] FACINELLI B, MARINI E, MAGI G, et al.Breast milk oligosaccharides:Effects of 2′-fucosyllactose and 6′-sialyllactose on the adhesion of Escherichia coli and Salmonella fyris to Caco-2 cells[J].The Journal of Maternal-Fetal & Neonatal Medicine, 2019, 32(17):2950-2952.
[7] HUANG D, YANG K X, LIU J, et al.Metabolic engineering of Escherichia coli for the production of 2′-fucosyllactose and 3-fucosyllactose through modular pathway enhancement[J].Metabolic Engineering, 2017, 41:23-38.
[8] NI Z J, LI Z K, WU J Y, et al.Multi-path optimization for efficient production of 2′-fucosyllactose in an engineered Escherichia coli C41 (DE3) derivative[J].Frontiers in Bioengineering and Biotechnology, 2020, 8:611900.
[9] LIU J J, KWAK S, PATHANIBUL P, et al.Biosynthesis of a functional human milk oligosaccharide, 2′-fucosyllactose, and L-fucose using engineered Saccharomyces cerevisiae[J].ACS Synthetic Biology, 2018, 7(11):2529-2536.
[10] YU S, LIU J J, YUN E J, et al.Production of a human milk oligosaccharide 2′-fucosyllactose by metabolically engineered Saccharomyces cerevisiae[J].Microbial Cell Factories, 2018, 17(1):1-10.
[11] HOLLANDS K, BARON C M, GIBSON K J, et al. Engineering two species of yeast as cell factories for 2′-fucosyllactose[J].Metabolic Engineering, 2019, 52:232-242.
[12] DENG J Y, GU L Y, CHEN T C, et al.Engineering the substrate transport and cofactor regeneration systems for enhancing 2′-fucosyllactose synthesis in Bacillus subtilis[J].ACS Synthetic Biology, 2019, 8(10):2418-2427.
[13] WAN L, ZHU Y Y, CHEN G, et al.Efficient production of 2′-fucosyllactose from L-fucose via self-assembling multienzyme complexes in engineered Escherichia coli[J].ACS Synthetic Biology, 2021, 10(10):2488-2498.
[14] PARK B S, CHOI Y H, KIM M W, et al.Enhancing biosynthesis of 2′-fucosyllactose in Escherichia coli through engineering lactose operon for lactose transport and α-1, 2-fucosyltransferase for solubility[J].Biotechnology and Bioengineering, 2022, 119(5):1264-1277.
[15] CHIN Y W, KIM J Y, LEE W H, et al.Enhanced production of 2′-fucosyllactose in engineered Escherichia coli BL21 star(DE3) by modulation of lactose metabolism and fucosyltransferase[J].Journal of Biotechnology, 2015, 210:107-115.
[16] LEE A R, LI L, SHIN S Y, et al.Soluble expression of the fucosyltransferase gene from Helicobacter pylori in Escherichia coli by co-expression of molecular chaperones[J].Microbiology and Biotechnology Letters, 2015, 43(3):212-218.
[17] LI Q, SUN B B, CHEN J, et al.A modified pCas/pTargetF system for CRISPR-Cas9-assisted genome editing in Escherichia coli[J].Acta Biochimica et Biophysica Sinica, 2021, 53(5):620-627.
[18] CHEN Q, WU H Y, JI M H, et al. Engineering a colanic acid biosynthesis pathway in E.coli for manufacturing 2′-fucosyllactose[J].Process Biochemistry, 2020, 94:79-85.
[19] JUNG S M, CHIN Y W, LEE Y G, et al.Enhanced production of 2′-fucosyllactose from fucose by elimination of rhamnose isomerase and arabinose isomerase in engineered Escherichia coli[J].Biotechnology and Bioengineering, 2019, 116(9):2412-2417.
[20] CHIN Y W, SEO N, KIM J H, et al. Metabolic engineering of Escherichia coli to produce 2′-fucosyllactose via salvage pathway of guanosine 5′-diphosphate (GDP)-L-fucose[J].Biotechnology and Bioengineering, 2016, 113(11):2443-2452.
[21] 李晨晨, 李梦丽, 江波, 等.2′-岩藻糖基乳糖的生物合成菌株构建及发酵条件研究[J].食品与发酵工业, 2021, 47(3):10-17.
LI C C, LI M L, JIANG B, et al.Strain development and fermentation optimization for biosynthesis of 2′-fucosyllactose[J].Food and Fermentation Industries, 2021, 47(3):10-17.
